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Abstract 
Review on del(5)(q32q33) EBF1/PDGFRB fusion 
with clinical data and genes involved. 
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Identity 
According to the recent revision to the WHO 
classification of myeloid neoplasm and acute 
leukemia (Arber et al, Blood, 2016), BCP-ALL with 
EBF1/PDGFRB fusion should be referred as 
'BCR/ABL1-like B-lymphoblastic 
leukemia/lymphoma' (provisional entity). 
BCR/ABL1-like ALL (or Ph-like ALL) lack the 
BCR/ABL1 fusion but demonstrate a gene 
expression profile and a poor outcome similar to 
BCR/ABL1-positive ALL (den Boer et al, Lancet 
Oncol, 2009). Kinase activating alterations 
(including the EBF1/PDGFRB fusion) are a 
hallmark of the disease and could be found in 
virtually all patients with BCR/ABL1-like ALL 
(Roberts et al, Cancer Cell 2012; Roberts et al, N 
Engl J Med, 2014). 
Clinics and pathology 
Disease 
B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL) 
Phenotype/cell stem origin 
B-cell precursor 
Epidemiology 
The EBF1/PDGFRB fusion accounts for about 0.5% 
of BCP-ALL, 3% of B-other ALL and 8% of BCR-
ABL1-like ALL (Schwab et al, Blood, 2016). The 
prevalence of EBF1/PDGFRB-positive ALL is 
expected to increase with age in parallel with the 
prevalence of BCR-ABL1-like ALL which ranges 
from 10% in children to 20% in adolescent and near 
30% in young adults. 
Clinics 
About 25 cases have been reported so far (Schwab et 
al, Blood, 2016; Lengline et al, Haematologica 2013; 
Weston et al, J Clin Oncol, 2013, Robert et al, 
Cancer Cell 2012; Roberts et al, N Engl J Med 2014). 
Patients were aged from 4 to 20y (median: 12y) and 
often displayed high leukocyte counts at 
presentation, especially in IKZF1-deleted cases. 
Treatment 
The detection of the EBF1/PDGFRB fusion is 
critical since the fusion protein could be targeted by 
tyrosine kinase inhibitors (TKIs) such as imatinib of 
dasatinib. Importantly, recent reports have shown 
successful TKI therapy even in patients refractory to 
conventional therapy. 
Evolution 
Patients with EBF1/PDGFRB-positive ALL are 
characterized by high levels of minimal residual 
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disease and a higher tendency of relapse compared 
with other ALL subtypes. However, there is 
evidence of durable remission especially after 
intensive chemotherapy. Finally, considering several 
reports, the use of TKIs should be assessed in 
EBF1/PDGFRB-positive patients and could 
decrease relapse rate and avoid the need of intensive 
chemotherapy. 
Cytogenetics 
Note 
The EBF1/PDGFRB is usually not seen by 
conventional karyotype. 
Cytogenetics morphological 
Karyotype is normal by conventional cytogenetics in 
half of the cases. The EBF1/PDGFRB fusion usually 
results from a cryptic 5q33 deletion requiring the use 
of fluorescent in situ hybridization (FISH), 
comparative genomic hybridization (CGH) or single 
nucleotide polymorphism (SNP)-array. Rarely, it 
could result from a t(5;5)(q32;q33.3) translocation or 
a complex 5q rearrangement. Additional cytogenetic 
events could include trisomy 5 (containing the EBF1 
and PDGFRB genes) or abnormal chromosome 5, 
deletion of the short arm of chromosome 9 as well as 
atypical aberrations. 
Cytogenetics molecular 
The EBF1/PDGFRB fusion results most often from 
a del(5)(q32q33.3) of about 8.6 Mb with breakpoints 
located within EBF1 and PDGFRB. 
Interestingly, multiplex ligation dependent probe  
amplification (MLPA) (SALSA MLPA kit P335 
IKZF1, MRC Holland) shows deletion of EBF1 exon 
16 in more than 70% of EBF1/PDGFRB-positive 
ALL (Schwab et al, Blood, 2016).  
Among the genes tested by MLPA, PAX5, IKZF1 
and/or CDKN2A/CDKN2B are often deleted. 
Genes involved and 
proteins 
Note 
The 5q33 deletion (more rarely t(5;5) translocation) 
leads to the fusion of EBF1 and PDGFRB. 
PDGFRB (platelet-derived growth 
factor receptor, beta polypeptide) 
Location 5q32 
DNA/RNA 
The PDGFRB gene contains 22 exons. 
Protein 
PDGFRB is a cell surface tyrosine kinase (TK) 
receptor for the platelet-derived growth factor 
family.  
PDGFRB belongs to the type III group of TKs 
(which also include KIT, FLT3 and CSF1 (the M-
CSF receptor)) and consists of five extracellular 
immunoglobulin-like domains, a single-spanning 
transmembrane domain and an intracellular kinase 
domain, split in two domains by a kinase insert. The 
TK domain is normally activated in response to 
ligand binding and receptor dimerization. PDGFRB 
is involved in embryonic development and 
modulation of hematopoietic cell functions. 
 
 
SNP-array karyotyping (Cytoscan HD, Affymetrix) showing a 5q33 deletion delimited by the PDGFRB and EBF1 genes (picture 
from Chromosome Analysis suite®)
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EBF1/PDGFRB protein fusion with functional domains 
 
EBF1 (early B-cell factor 1) 
Location 5q33.3 
DNA/RNA 
The EBF1 gene contains 16 exons. 
Protein 
EBF1 is a transcription factor critical for B cell 
differentiation, signal transduction and function. 
EBF family proteins consist of an N-terminal DNA-
binding domain including a zinc binding motif, 
designated as "zinc-knuckle", a transcription factor 
immunoglobulin (TIG) domain and a helix-loop-
helix domain, followed by a C-terminal 
transactivation domain. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
The hybrid gene The fusion usually involved 
PDGFRB exon 11 fused to EBF1 exon15 (rarely 
alternative breakpoints involving EBF1 exon 14). 
Detection 
FISH detection with PDGFRB and EBF1 breakapart 
probes or identification of the EBF1/PDGFRB 
transcript fusion by ligation-dependent reverse 
transcriptase-polymerase chain reaction (LD-
RTPCR). 
Fusion protein 
Description 
The fusion consists of the in-frame fusion of the N-
terminal part of the transcription factor EBF1, 
including the DNA-binding domain, with the 
tyrosine kinase domain of PDGFRB. 
Oncogenesis 
The tyrosine kinase domain of the fusion protein is 
constitutively activated, triggering downstream  
 
signalling. 
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